INNOVATIVE EYEWEAR INC (LUCY) Stock Fundamental Analysis
USA - NASDAQ:LUCY - US45791D2080 - Common Stock
1.56 USD
+0.01 (+0.65%)
1.54 USD
-0.02 (-1.28%)
We assign a fundamental rating of 4 out of 10 to LUCY. LUCY was compared to 188 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for LUCY as it has an excellent financial health rating, but there are worries on the profitability. LUCY is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
LUCY had negative earnings in the past year.
In the past year LUCY has reported a negative cash flow from operations.
LUCY had negative earnings in each of the past 5 years.
LUCY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LUCY has a worse Return On Assets (-64.77%) than 69.68% of its industry peers.
Looking at the Return On Equity, with a value of -68.55%, LUCY is in line with its industry, outperforming 44.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.77% | ||
| ROE | -68.55% | ||
| ROIC | N/A |
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LUCY's Gross Margin of 18.24% is on the low side compared to the rest of the industry. LUCY is outperformed by 80.32% of its industry peers.
LUCY's Gross Margin has declined in the last couple of years.
LUCY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.24% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
LUCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
LUCY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LUCY has been reduced compared to 5 years ago.
LUCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
LUCY has an Altman-Z score of 2.13. This is not the best score and indicates that LUCY is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.13, LUCY is doing good in the industry, outperforming 63.30% of the companies in the same industry.
LUCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.13 |
ROIC/WACCN/A
WACC8.74%
2.3 Liquidity
A Current Ratio of 18.70 indicates that LUCY has no problem at all paying its short term obligations.
LUCY has a Current ratio of 18.70. This is amongst the best in the industry. LUCY outperforms 99.47% of its industry peers.
LUCY has a Quick Ratio of 15.93. This indicates that LUCY is financially healthy and has no problem in meeting its short term obligations.
LUCY's Quick ratio of 15.93 is amongst the best of the industry. LUCY outperforms 99.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.7 | ||
| Quick Ratio | 15.93 |
3. Growth
3.1 Past
LUCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.60%, which is quite impressive.
The Revenue has grown by 29.29% in the past year. This is a very strong growth!
Measured over the past years, LUCY shows a very strong growth in Revenue. The Revenue has been growing by 33.36% on average per year.
EPS 1Y (TTM)70.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.71%
Revenue 1Y (TTM)29.29%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%87.57%
3.2 Future
LUCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.87% yearly.
Based on estimates for the next years, LUCY will show a very strong growth in Revenue. The Revenue will grow by 224.44% on average per year.
EPS Next Y69.87%
EPS Next 2Y39.87%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year110.53%
Revenue Next 2Y224.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LUCY. In the last year negative earnings were reported.
Also next year LUCY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LUCY's earnings are expected to grow with 39.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3YN/A
5. Dividend
5.1 Amount
LUCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.56
+0.01 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners4.48%
Inst Owner Change97.52%
Ins Owners22.18%
Ins Owner Change0%
Market Cap7.13M
Revenue(TTM)1.98M
Net Income(TTM)-7.73M
Analysts82.86
Price Target5.1 (226.92%)
Short Float %1.25%
Short Ratio0.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.64%
Min EPS beat(2)3.3%
Max EPS beat(2)15.97%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-49.31%
Min Revenue beat(2)-55.39%
Max Revenue beat(2)-43.24%
Revenue beat(4)0
Avg Revenue beat(4)-50.82%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)-32.28%
Revenue beat(8)2
Avg Revenue beat(8)0.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.87%
EPS NY rev (1m)0%
EPS NY rev (3m)9.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-60%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-46.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.63 | ||
| P/tB | 0.66 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.24
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-1.75
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS0.43
BVpS2.47
TBVpS2.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.77% | ||
| ROE | -68.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.24% | ||
| FCFM | N/A |
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
F-Score4
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 146.59% | ||
| Cap/Sales | 10.96% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.7 | ||
| Quick Ratio | 15.93 | ||
| Altman-Z | 2.13 |
F-Score4
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)402.41%
Cap/Depr(5y)N/A
Cap/Sales(3y)23.82%
Cap/Sales(5y)37.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.71%
EPS Next Y69.87%
EPS Next 2Y39.87%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)29.29%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%87.57%
Revenue Next Year110.53%
Revenue Next 2Y224.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.18%
OCF growth 3YN/A
OCF growth 5YN/A
INNOVATIVE EYEWEAR INC / LUCY FAQ
Can you provide the ChartMill fundamental rating for INNOVATIVE EYEWEAR INC?
ChartMill assigns a fundamental rating of 4 / 10 to LUCY.
What is the valuation status for LUCY stock?
ChartMill assigns a valuation rating of 1 / 10 to INNOVATIVE EYEWEAR INC (LUCY). This can be considered as Overvalued.
What is the profitability of LUCY stock?
INNOVATIVE EYEWEAR INC (LUCY) has a profitability rating of 0 / 10.
What is the financial health of INNOVATIVE EYEWEAR INC (LUCY) stock?
The financial health rating of INNOVATIVE EYEWEAR INC (LUCY) is 8 / 10.
What is the earnings growth outlook for INNOVATIVE EYEWEAR INC?
The Earnings per Share (EPS) of INNOVATIVE EYEWEAR INC (LUCY) is expected to grow by 69.87% in the next year.